- Home
- FDS vs DGX Comparison
FDS vs DGX Comparison
Compare FDS & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FDS
- DGX
- Stock Information
- Founded
- FDS 1978
- DGX 1967
- Country
- FDS United States
- DGX United States
- Employees
- FDS N/A
- DGX N/A
- Industry
- FDS Computer Software: Programming Data Processing
- DGX Medical Specialities
- Sector
- FDS Technology
- DGX Health Care
- Exchange
- FDS Nasdaq
- DGX Nasdaq
- Market Cap
- FDS 17.6B
- DGX 20.5B
- IPO Year
- FDS 1996
- DGX 1996
- Fundamental
- Price
- FDS $285.08
- DGX $182.55
- Analyst Decision
- FDS Hold
- DGX Buy
- Analyst Count
- FDS 10
- DGX 15
- Target Price
- FDS $356.78
- DGX $194.07
- AVG Volume (30 Days)
- FDS 767.2K
- DGX 1.1M
- Earning Date
- FDS 09-18-2025
- DGX 10-21-2025
- Dividend Yield
- FDS 1.54%
- DGX 1.76%
- EPS Growth
- FDS 11.79
- DGX 14.49
- EPS
- FDS 15.55
- DGX 8.51
- Revenue
- FDS $2,321,748,000.00
- DGX $10,850,000,000.00
- Revenue This Year
- FDS $6.17
- DGX $11.17
- Revenue Next Year
- FDS $5.44
- DGX $3.48
- P/E Ratio
- FDS $18.35
- DGX $21.40
- Revenue Growth
- FDS 5.39
- DGX 13.74
- 52 Week Low
- FDS $272.50
- DGX $148.70
- 52 Week High
- FDS $499.87
- DGX $197.55
- Technical
- Relative Strength Index (RSI)
- FDS 38.48
- DGX 47.48
- Support Level
- FDS $285.50
- DGX $179.53
- Resistance Level
- FDS $296.80
- DGX $197.55
- Average True Range (ATR)
- FDS 7.61
- DGX 4.22
- MACD
- FDS 3.89
- DGX -0.38
- Stochastic Oscillator
- FDS 48.91
- DGX 21.09
About FDS FactSet Research Systems Inc.
FactSet provides financial data and portfolio analytics to the global investment community. The company aggregates data from third-party data suppliers, news sources, exchanges, brokerages, and contributors into its workstations. In addition, it provides essential portfolio analytics that companies use to monitor portfolios and address reporting requirements. Buy-side clients (including wealth and corporate clients) account for roughly 82% of FactSet's annual subscription value. In 2015, the company acquired Portware, a provider of trade execution software. In 2017, it acquired BISAM, a risk management and performance measurement provider. In 2022, it completed its purchase of CUSIP Global Services.
About DGX Quest Diagnostics Incorporated
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.